Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $7,686 | $7,403 | $3,438 | $4,993 |
| - Cash | $320 | $991 | $156 | $176 |
| + Debt | $368 | $481 | $366 | $366 |
| Enterprise Value | $7,734 | $6,893 | $3,648 | $5,183 |
| Revenue | $0 | $8 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$2 | $7 | -$1 | -$1 |
| % Margin | – | 81.8% | – | – |
| EBITDA | -$139 | -$128 | -$92 | -$95 |
| % Margin | – | -1,556.2% | – | – |
| Net Income | -$132 | -$133 | -$96 | -$100 |
| % Margin | – | -1,608.8% | – | – |
| EPS Diluted | -0.73 | -0.76 | -0.61 | -0.63 |
| % Growth | 3.9% | -24.6% | 3.2% | – |
| Operating Cash Flow | -$120 | -$97 | -$73 | -$77 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$2 |
| Free Cash Flow | -$120 | -$98 | -$73 | -$79 |